focus -WSS

focus

author：leisure time 2025-09-30 00:39:23 - browse：227

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FDA panel to weigh safety of artificial wombs for preterm births

WSS

Ebola vaccine can save some who are already sick, per new study

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Abbott's new heart device gets FDA advisory panel nod

Covid’s new normal has set in amid another rise in cases

Congress must protect the remaining independent doctors

Akili changes sales model for its ADHD video game treatment

knowledge

focus

focus

Hepatitis C has a cure — but many Americans still lack access to it

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Hepatitis C has a cure — but many Americans still lack access to it

Information blocking fines are now fair game in health care

Activists slam private health insurers over coverage restrictions

Doctors on social media are being harassed and cyberbullied

Tori Bowie and the unacceptable rates of Black maternal death

Artificial intelligence use in health care faces greater scrutiny in 2024

What does generative AI mean for health care? We asked experts

Patients, doctors press FTC to beef up hospital merger scrutiny

hotspot

Long Covid research funding gets a major boost from NIH

Abbott's new heart device gets FDA advisory panel nod

PBMs drew scrutiny in House hearing — and so did pharma

STAT Boddities: What happens to the brain when we get scared?

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Resistance to opioid

focus

knowledge

leisure time

knowledge